230 related articles for article (PubMed ID: 26919549)
1. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine.
Felipe CR; Oliveira NI; Hannun PG; de Paula MI; Tedesco-Silva H; Medina-Pestana JO
Ther Drug Monit; 2016 Feb; 38(1):64-72. PubMed ID: 26274696
[TBL] [Abstract][Full Text] [Related]
3. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
5. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil.
Traitanon O; Mathew JM; Shetty A; Bontha SV; Maluf DG; El Kassis Y; Park SH; Han J; Ansari MJ; Leventhal JR; Mas V; Gallon L
PLoS One; 2019; 14(5):e0216300. PubMed ID: 31136582
[TBL] [Abstract][Full Text] [Related]
7. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
8. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
11. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
Felipe C; Ferreira A; Bessa A; Abait T; Perez JD; Casarini DE; Medina-Pestana J; Tedesco H
Ther Drug Monit; 2018 Feb; 40(1):52-58. PubMed ID: 29271815
[TBL] [Abstract][Full Text] [Related]
12. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center.
Ciancio G; Tryphonopoulos P; Gaynor JJ; Guerra G; Sageshima J; Roth D; Chen L; Kupin W; Mattiazzi A; Tueros L; Flores S; Hanson L; Powell RH; Ruiz P; Vianna R; Burke GW
Transplant Proc; 2016; 48(6):2006-10. PubMed ID: 27569936
[TBL] [Abstract][Full Text] [Related]
13. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
Ueno P; Felipe C; Ferreira A; Cristelli M; Viana L; Mansur J; Basso G; Hannun P; Aguiar W; Tedesco Silva H; Medina-Pestana J
Transplantation; 2017 Apr; 101(4):844-850. PubMed ID: 27490418
[TBL] [Abstract][Full Text] [Related]
14. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
[TBL] [Abstract][Full Text] [Related]
15. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial.
Pascher A; De Simone P; Pratschke J; Salamé E; Pirenne J; Isoneimi H; Bijarnia M; Krishnan I; Klupp J
Am J Transplant; 2015 May; 15(5):1283-92. PubMed ID: 25677074
[TBL] [Abstract][Full Text] [Related]
17. A Head-to-head Comparison of De Novo Sirolimus or Everolimus Plus Reduced-dose Tacrolimus in Kidney Transplant Recipients: A Prospective and Randomized Trial.
Toniato de Rezende Freschi J; Cristelli MP; Viana LA; Ficher KN; Nakamura MR; Proença H; Dreige YC; de Marco R; de Lima MG; Foresto RD; Aguiar WF; Medina-Pestana J; Tedesco-Silva H
Transplantation; 2024 Jan; 108(1):261-275. PubMed ID: 37525373
[TBL] [Abstract][Full Text] [Related]
18. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
[TBL] [Abstract][Full Text] [Related]
19. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Miranda TA; Felipe CR; Santos RHN; Medina Pestana JO; Tedesco-Silva Junior H
Ther Drug Monit; 2020 Dec; 42(6):811-820. PubMed ID: 32657909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]